A5045832805- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- PI3K/AKT/mTOR signaling in cancer
- Gastric Cancer Management and Outcomes
- Inflammatory Biomarkers in Disease Prognosis
- HER2/EGFR in Cancer Research
- RNA modifications and cancer
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
- Hepatocellular Carcinoma Treatment and Prognosis
- Esophageal Cancer Research and Treatment
- Peptidase Inhibition and Analysis
- Gut microbiota and health
- Medical Imaging Techniques and Applications
- Neutropenia and Cancer Infections
- Immune cells in cancer
Showa University
2020-2025
Showa University Hospital
2022
Japanese Foundation For Cancer Research
2012-2021
The Cancer Institute Hospital
2007-2021
Weatherford College
2021
Kubota (Japan)
2021
Thoracic Surgery Foundation
2020
Tokyo National Hospital
2004-2010
Kanazawa University
2010
Tokyo Medical University
2010
The anaplastic lymphoma kinase (ALK) fusion oncogene is observed in 3%-5% of non-small cell lung cancer (NSCLC). Crizotinib and ceritinib, a next-generation ALK tyrosine inhibitor (TKI) active against crizotinib-refractory patients, are clinically available for the treatment ALK-rearranged NSCLC multiple ALK-TKIs currently under clinical evaluation. These exhibit robust activity patients; however, emergence ALK-TKI resistance restricts therapeutic effect. To date, various secondary mutations...
Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due acquired resistance, such as secondary mutations ALK including I1171N and G1202R. Although ceritinib or lorlatinib was be effective these resistant mutants, further resistance often emerges ALK-compound following the use of lorlatinib. However, drug for overcoming not been established yet.We lorlatinib-resistant cells harboring ALK-I1171N -G1202R...
Abstract Mutations in the ALK gene are detectable approximately 40% of ALK-rearranged lung cancers resistant to inhibitors. Although epithelial-to-mesenchymal transition (EMT) is a mechanism resistance various targeted drugs, its involvement inhibitor largely unknown. In this study, we report that both ALK-mutant L1196M and EMT were concomitantly detected single crizotinib-resistant lesion patient with cancer. Digital PCR analyses combined microdissection after IHC staining for markers...
9004 Background: Despite advances in first-line (1L) immunotherapy ± CT, most patients (pts) with aNSCLC experience disease progression, necessitating novel strategies. Dato-DXd is an antibody drug conjugate (ADC) composed of a humanized anti-TROP2 IgG1 monoclonal covalently linked to topoisomerase I inhibitor payload via plasma-stable tetrapeptide-based cleavable linker. had encouraging efficacy and manageable safety heavily pretreated aNSCLC. + yielded greater preclinical activity than...
A secondary epidermal growth factor receptor ( EGFR ) mutation, the substitution of threonine 790 with methionine (T790M), leads to acquired resistance reversible ‐tyrosine kinase inhibitors ‐ TKI s). non‐invasive method for detecting T790M mutation would be desirable direct patient treatment strategy. Plasma DNA samples were obtained after discontinuation gefitinib or erlotinib in 75 patients non‐small cell lung cancer NSCLC ). was amplified using SABER (single allele base extension...
Introduction:Anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) is sensitive to ALK inhibitors, but resistance develops. This study assessed the maximum-tolerated dose, safety, pharmacokinetics (PK), and antitumor activity of ceritinib, a novel inhibitor (ALKi), in Japanese patients with ALK-rearranged malignancies.Methods:This phase I, multicenter, open-label (NCT01634763) enrolled adult (by fluorescence situ hybridization and/or immunohistochemistry) locally...
HSP90 is involved in stability and function of cancer-related proteins. This study was conducted to define the MTD, safety, pharmacokinetics, pharmacodynamics, preliminary antitumor efficacy TAS-116, a novel class, orally available, highly selective inhibitor HSP90. Patients with advanced solid tumors received TAS-116 once daily (QD, step 1) or every other day (QOD, 2) 21-day cycles. Each comprised dose escalation phase determine MTD an expansion at MTD. In phase, accelerated dose-titration...
To diagnose small cell lung carcinoma (SCLC), neuroendocrine (NE) phenotype markers such as chromogranin A, synaptophysin, and CD56 are helpful. However, because they dispensable, SCLCs occur without apparent NE phenotypes. Insulinoma-associated protein 1 (INSM1) is a transcription factor for differentiation has emerged single practical marker SCLC. Using the surgical samples of 141 pulmonary tumors (78 SCLCs, 44 large carcinomas, 19 carcinoids), 246 non-NE we examined immunohistochemical...
Few clinical trials have been specifically designed for elderly patients with advanced non-small cell lung cancer (NSCLC), and the anticipated increase in number of such has prompted a search new treatment options that provide greater palliative benefit.To determine whether carboplatin plus pemetrexed followed by maintenance is noninferior compared docetaxel monotherapy regard to overall survival (OS) nonsquamous NSCLC.This open-label, multicenter, noninferiority phase 3 randomized trial was...
Immune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays role in the microenvironment, affecting treatment response. The gut is highly individual, and varies with factors, such as age race. composition Japanese patients efficacy of immunotherapy remain unknown.We investigated 26 solid tumors prior to immune inhibitor monotherapy identify bacteria involved these drugs immune-related adverse events (irAEs).The genera Prevotella Parabacteroides were...
Abstract The low response rate of immune checkpoint inhibitors (ICIs) is a challenge. efficacy ICIs influenced by the tumour microenvironment, which controlled gut microbiota. In particular, intestinal bacteria and their metabolites, such as short chain fatty acids (SCFAs), are important regulators cancer immunity; however, our knowledge on effects individual SCFAs remains limited. Here, we show that isobutyric acid has strongest effect among both activity growth. vitro, cell numbers were...
The epidermal growth factor receptor (EGFR) mutation status has emerged as a validated biomarker for predicting the response to treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKI) in patients non-small cell lung cancer. However, responses EGFR-TKIs vary even among EGFR mutations. We studied several other independently active biomarkers EGFR-TKI treatment.We retrospectively analyzed serum concentrations of 13 molecules cohort 95 adenocarcinoma who received at three centers. pretreatment...
Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) agent, is effective and well tolerated in patients with pretreated advanced non-small-cell lung cancer (NSCLC). We assessed its efficacy safety Japanese through subgroup analyses of the phase 3 OAK study (NCT02008227).Key eligibility criteria this randomized, controlled, open-label, international include locally advanced/metastatic NSCLC, ≥ prior platinum-based chemotherapy, age 18 years, measurable disease (Response Evaluation Criteria...
Abstract The treatment for anaplastic lymphoma kinase (ALK)‐positive lung cancer has been rapidly evolving since the introduction of several ALK tyrosine inhibitors (ALK‐TKI) in clinical practice. However, acquired resistance to these drugs become an important issue. In this study, we collected a total 112 serial biopsy samples from 32 patients with ALK‐positive during multiple ALK‐TKI treatments reveal mechanisms ALK‐TKI. Among patients, 24 received more than two Secondary mutations were...
Abstract Immune checkpoint inhibitor discovery represents a turning point in cancer treatment. However, the response rates of solid tumors remain ~10%–30%; consequently, prognostic and immune‐related adverse event (irAE) predictors are being explored. The programmed cell death protein 1 (PD‐1) receptor occupancy (RO) PD‐1 inhibitors depends on number peripheral blood lymphocytes their expression levels, suggesting that RO may be related to efficacy events. As inhibition affects each T‐cell...
In patients with cancer, sarcopenia is an indicator of poor prognosis and associated increased risk chemotherapy-related adverse events. Skeletal muscle interacts the immune system, senescence. However, association between response to checkpoint inhibitor (ICI) therapy remains unclear. This retrospective study included advanced or recurrent non-small cell lung cancer treated nivolumab pembrolizumab monotherapy. The psoas index (PMI) both clinical immune-related events (irAEs) was assessed...
Developing predictive biomarkers for immune checkpoint inhibitors (ICIs) is important. Programmed cell death protein-1 (PD-1) receptor occupancy by anti-PD-1 antibodies on circulating T cells varies among patients. However, the association between exhaustion of these antibody-bound and clinical efficacy ICIs remains unknown. Therefore, present study was aimed at evaluating this association. This prospective cohort included patients with advanced non-small lung cancer (NSCLC) esophageal...
BACKGROUND Drug-induced lung injury is a common adverse effect of chemotherapeutic agents. Diffuse alveolar hemorrhage (DAH) fatal complication associated with drug-induced injury. Early diagnosis and treatment DAH critical, as delayed management can lead to respiratory failure poor outcomes. However, the difficult because nonspecific clinical manifestations; such, bronchoscopy necessary establish diagnosis. CASE SUMMARY The patient presented fever dry cough. He had been receiving...